Tracon Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation
Common stock issued for services
Depreciation and amortization
Noncash interest
Amortization of debt discount
Amortization of premium/discount on short-term investments
Lease asset amortization and liability accretion, net
Equity ownership license revenue
Impairment of private company equity ownership

Changes in assets and liabilities:
Prepaid expenses and other assets
Accounts payable and accrued expenses
Accrued compensation and related expenses
Net cash provided by (used in) operating activities
Cash flows from investing activities
Purchase of property and equipment
Purchases of available-for-sale short-term investments
Proceeds from the maturity of available-for-sale short-term investments
Proceeds from the maturity of short-term investments
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from long-term debt
Proceeds from arbitration financing
Proceeds from long-term debt and arbitration financing
Repayment of long-term debt and arbitration financing payable
Proceeds from sale of common stock and warrants, net of offering costs
Payment of tax withholdings related to net share settlements of vested restricted stock awards
Proceeds from issuance of common stock under equity plans, net of tax withholdings
Proceeds from issuance of common stock under equity plans
Net cash (used in) provided by financing activities

Change in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosure of cash flow information
Interest paid
Supplemental schedule of noncash investing and financing activities
Issuance of common stock in connection with common stock purchase agreement
Issuance of common stock warrants in connection with long-term debt

Comments